



UNIVERSITÄT
DES
SAARLANDES

Universität des Saarlandes (UDS)

5TH INTERNATIONAL SYMPOSIUM

*Vitamin D and
Analogues in Cancer
Prevention and
Therapy*

MAY 02 – 03, 2014
HOTEL KREFELDER HOF
KREFELD, GERMANY




Table of content

WELCOME	3
FEATURED LECTURES FRIDAY, MAY 02, 2014	4
FEATURED LECTURES SATURDAY, MAY 3, 2014	8
SATELLITE SYMPOSIUM	10
REGISTRATION FORM	11
REGISTRATION FEES	12
PAYMENT DETAILS	13
GENERAL TERMS AND CONDITIONS	14
POSTER	16
FACULTY	18
POSTER AUTHORS	19
GENERAL INFORMATION	20
UNDER THE AUSPICES OF / SUPPORTED BY	22
SPECIAL THANKS TO OUR SPONSORS	23


Welcome

DEAR COLLEAGUES,

This time it's Krefeld, again! On behalf of the scientific committee it is a pleasure to invite you to the 5th International Symposium Vitamin D and Analogs in Cancer Prevention and Therapy.

During the past years our knowledge about molecular biology, metabolism and biologic effects of vitamin D and analogs has exploded. These findings have lead to new concepts for the application of vitamin D and analogs to cancer, and it is obvious that enormous progress is beeing made on this area. This meeting is specifically designed to offer scientists and clinicians insights into the latest developments in this intriguing research area. The program will include keynote lectures as well as free communications. You are cordially invited to join this meeting.

We hope to see you soon in Krefeld!



Michael Friedrich



Jörg Reichrath



Thomas Vogt

Featured lectures

FRIDAY, MAY 02, 2014

8.00 – 8.15 am

Opening remarks

Welcome address by the Lord Mayor of Krefeld

Gregor Kathstede

Michael Friedrich (Krefeld, D)

Jörg Reichrath (Homburg/Saar, D)

I Historic and Future Perspectives of Vitamin D

Chair: *JoEllen Welsh (Rensselaer, USA)*

Klaus Römer (Homburg/Saar, D)

8.15 – 9.00 am

An Update on the Healthful Benefits of Vitamin D

[Abstract No. 1]

Michael F. Holick (Boston, USA)

II MOLECULAR BIOLOGY OF VITAMIN D:
A GENOME-WIDE PERSPECTIVE

Chair: *JoEllen Welsh (Rensselaer, USA)*

Klaus Römer (Homburg/Saar, D)

9.00 – 9.30 am

The impact of a harmonized genomic view on vitamin D
receptor locations on understanding the actions of vitamin D

[Abstract No. 2]

Carsten Carlberg, (Kuopio, FIN)

9.30 – 10.00 am

The Regulation of Gene Expression by 1,25-Dihydroxyvitamin
D3 in Target Cells: New Principles and Increased Complexities

[Abstract No. 3]

J. Wesley Pike (Madison, USA)

10.00 – 10.15 am

Novel insights into VDR structure-function

[Abstract No. 4]

Natacha Rochel, (Illkirch, F)

10.15 – 10.45 am

Coffee break, technical exhibition and poster viewing

Featured lectures

FRIDAY, MAY 02, 2014

III VITAMIN D COMPOUNDS: IMPLICATIONS FOR CANCER

Chair: *Carsten Carlberg (Kuopio, FIN)*

Reinhold Vieth (Toronto, CAN)

10.45 -11.15 am

The delicate balance of CYP27B1 and CYP24A1 in ensuring
optimal 1,25-(OH)2D3 concentrations for human health
[Abstract No. 5]

Glenville Jones (Kingston, CAN)

11.15 – 11.30 am

Development of efficient chemical syntheses of Vitamin D
degradation products [Abstract No. 6]

Lars Kattner (Saarbrücken, D)

11.30 – 11.45 am

Synthesis, docking studies and biological evaluation of
19-norcalcitriol analogs with distorted intericyclic diene system
[Abstract No. 7]

Katarzyna Sokolowska (Warsaw, PL)

11.45 – 00.05 pm

Pre-clinical Studies of MART-10, a Less Calcemic Vitamin D
Analog, for Cancer Prevention and Treatment [Abstract No. 8]

Tai C. Chen (Boston, USA)

0.05 – 1.05 pm

Lunch break, technical exhibition and poster viewing

IV VITAMIN D AND UV-RADIATION IN CANCER PREVENTION (I)

Chair: *Michael F. Holick (Boston, USA)*

Jörg Reichrath (Homburg/Saar, D)

1.05 – 1.35 pm

Vitamin D and Cancer: Evidence from Epidemiological Studies
[Abstract No. 9]

William B. Grant (San Francisco, USA)

1.35 – 2.05 pm

Vitamin D & Cancer: Evidence from the ESTHER and other
epidemiological studies [Abstract No. 10]

José Manuel Ordóñez-Mena (Heidelberg, D)

Featured lectures

FRIDAY, MAY 02, 2014

2.05 – 2.25 pm

Vitamin D Status and Cancer Incidence of Hemodialysis (HD) Patients in D [Abstract No. 11]
Rolfdieter Krause (Berlin, D)

2.25 – 2.55 pm

UV-radiation and melanoma. Current concepts [Abstract No. 12]
Johan Emilian Moan (Oslo, N)

2.55 – 3.25 pm

Coffee break, technical exhibition and poster viewing

V VITAMIN D AND UV-RADIATION IN CANCER PREVENTION (II)

Chair: *William B. Grant (San Francisco, USA)*
Johan Emilian Moan (Oslo, N)

3.25 – 3.55 pm

Beneficial effects of UV radiation on diseases other than cancer: an update [Abstract No.13]
Asta Juzeniene (Oslo, N)

3.55 – 4.25 pm

Vitamin D in preventive medicine [Abstract No. 14]
Winfried März (Graz, A)

4.25 – 4.55 pm

Vitamin D and Cardiovascular Disease [Abstract No.15]
Armin Zittermann (Bad Oeynhausen, D)

4.55 – 5.25 pm

Break, technical exhibition and poster viewing

VI VITAMIN D COMPOUNDS IN GYNECOLOGICAL MALIGNANCIES AND IN LYMPHOMA

Chair: *Michael Friedrich (Krefeld, D)*
Frank R. De Grujil (Leiden, NL)

5.25 – 5.55 pm

Vitamin D signaling in Triple Negative Breast Cancer [Abstract No. 16]
JoEllen Welsh (Rensselaer, USA)

Featured lectures

FRIDAY, MAY 02, 2014

5.55 – 6.10 pm

Vitamin D Inhibits the Proliferation of Ovarian Cancer Cell Lines and Suppresses the Expression of Cyclooxygenase-2 [Abstract No. 17]
Marc Thill (Frankfurt, D)

6.10 – 6.40 pm

Vitamin D deficiency impairs Rituximab-mediated cellular cytotoxicity [Abstract No. 18]
Jörg Thomas Bittenbring (Homburg/Saar, D)

6.40 – 6.55 pm

Vitamin D and risk of non-Hodgkin lymphoma including cutaneous T-cell lymphoma [Abstract No. 19]
Chahid Assaf (Krefeld, D)

GET-TOGETHER

Friday, May 02, 2014 at 7.30 pm at
Krefelder Rennbahn
An der Rennbahn 4 | 47800 Krefeld, Germany



Featured lectures

SATURDAY, MAY 3, 2014

VII VITAMIN D COMPOUNDS IN SKIN CANCER

Chair: *J. Wesley Pike (Madison, USA)*
Thomas Vogt (Homburg/Saar, D)

8.00 – 8.30 am

Role of vitamin D in human skin cancers [Abstract No. 20]

Jörg Reichrath (Homburg/Saar, D)

8.30 – 9.00 am

Vitamin D and melanoma [Abstract No. 21]

Julia A. Newton-Bishop (Leeds, UK)

9.00 – 9.30 am

Vitamin D and cancer prevention: animal models and observational data in renal transplant patients [Abstract No. 22]

Frank R. De Gruijl (Leiden, NL)

9.30 – 10.00 am

Calcitriol – a potent Hedgehog signaling inhibitor [Abstract No. 23]

Anja Uhlmann (Göttingen, D)

10.00 – 10.30 am

Coffee break, technical exhibition and poster viewing

VIII VITAMIN D COMPOUNDS: IMPLICATIONS FOR CANCER

Chair: *Glenville Jones (Kingston, CAN)*
Winfried März (Graz, A)

10.30 – 10.45 am

Calcitriol negatively regulates Smoothend activity by binding its CRD [Abstract No. 24]

Benedikt Albert (Göttingen, D)

10.45 – 11.00 am

Antiproliferative and proapoptotic effects of vitamin D analogues in keratinocytes indicate a novel therapeutic strategy against non-melanoma skin cancer [Abstract No. 25]

Christoph C. Geilen (Hamburg, D)

Featured lectures

SATURDAY, MAY 3, 2014

11.00 – 11.30 am

Preclinical and Epidemiologic Observations – Cancer and Vitamin D: Are There Clinical Applications? [Abstract No. 26]

Donald L. Trump (Buffalo, USA)

11.30 – 0.00 pm

Latitude as a Confounder for Prostate Cancer U-Shaped Risk Curves in Relation to Serum 25-Hydroxyvitamin D: a Meta-Analysis of Case-Control and Cohort Studies [Abstract No. 27]

Reinhold Vieth (Toronto, CAN)

0.00 – 0.30 pm

A Perspective on the Raging D-Bate about the Health Benefits of Vitamin D [Abstract No. 28]

Michael F. Holick (Boston, USA)

0.30 – 1.00 pm

Round Table Discussion

Vitamin D and analogs: a new era in cancer prevention and treatment?

Chair: *Donald L. Trump (Buffalo, USA)*

1.00 – 1.10 pm

Concluding remarks

Jörg Reichrath (Homburg/Saar, D)

Michael Friedrich (Krefeld, D)

1.10 - 2.30 pm

Lunch break, technical exhibition and poster viewing

Posters and technical exhibition will be displayed throughout the meeting

Featured lectures

SATURDAY, MAY 3, 2014

SATELLITE SYMPOSIUM

Chair: *Michael Friedrich (Krefeld, D)*
Jörg Reichrath (Homburg/Saar, D)

2.30 - 3.00 pm

Die erweiterte Bedeutung des Sonnenhormons Vitamin D für unsere Gesundheit – kaum entdeckt und schon verloren!
[Abstract No. 29]

Jörg Spitz (Schlangenbad, D)

3.00 - 3.30 pm

Vitamin D und Osteoporose:
was ist für den klinischen Alltag wichtig? [Abstract No. 42]

Clayton Kraft (Krefeld, D)

3.30 - 4.00 pm

Vitamin D in der onkologischen Intervention:
wichtige Aspekte für die Praxis. [Abstract No. 30]

Uwe Gröber (Essen, D)

4.00 - 4.30 pm

UV, Vitamin D und Hautkrebs:
wie viel Sonne braucht der Mensch? [Abstract No. 31]

Jörg Reichrath (Homburg/Saar, D)

„AUF WIEDERSEHEN AND GOOD BYE“

Registration form

Please complete this form and fax back to **+49 (0) 211 - 770589 - 29**, or scan and e-mail your response to **info@medical-communications.de** or register online at **www.medical-communications.de**

For organizational reasons we kindly ask for registration in advance. However, on-site registration is possible.

I will join the **5th International Symposium**
“**Vitamin D and Analogs in Cancer Prevention and Therapy**”
May 02 - 03, 2014 in Krefeld, Germany

Name		<input type="radio"/> Ms.	<input type="radio"/> Mr.	Title
First name				
Hospital / Institute / Division				
Street				
Zip code		City		
Country		<input type="radio"/> Private address	<input type="radio"/> Hospital address	
Telephone		Telefax		
E-Mail (for your registration confirmation)				

I hereby confirm that the e-mail address could be used for further information reasons.

X

Signature / Place / Date

Registration Fees

CONFERENCE TICKET

2 days incl. Satellitensymposium, per person € 300,-*

REDUCED PRICE

for students, per person € 100,-*

CONFERENCE TICKET

Saturday afternoon (Satellitensymposium only) € 50,-*

All tickets include lunch, coffee breaks and softdrinks during the conference.

EVENING RECEPTION

May 02, 2014 € 30,-*

The ticket includes food and beverage.

TOTAL AMOUNT

€ -----
*19% VAT inclusively

NOTE:

Reservations by fax or online registration will be accepted and confirmed upon presentation of a direct debiting order for a German bank account or after receipt of the credited amount via credit card.

Sorry – registrations by phone or email cannot be accepted.

X

Signature / Place / Date

Payment details

DEBIT ADVICE (ONLY POSSIBLE WITHIN EUROPE)

I hereby authorize bsh medical communications GmbH to charge my bank account / credit card listed below for payment of all fees when due and expressly waive the obligatory pre-notification of 14 calendar days.

Creditor identification number:
DE 52ZZZ00001018794 / VAT ID: DE288230703

Bank name

Bank identification code / BIC / SWIFT

IBAN

Account holder

I herewith register obligatory for participation in the Symposium "Vitamin D and Analogs in Cancer Prevention and Therapy", 2014 and accept the General Terms and Conditions.

X

Signature / Place / Date

CREDIT CARD (MASTER CARD OR VISA) FOR PARTICIPANTS OF COUNTRIES OUTSIDE EUROPE (NON-RESIDENT PARTICIPANTS) ONLY

Master Card VISA

Name of cardholder

Credit card number

Valid till (MM / JJ)

Verification code

X

Signature / Place / Date

General Terms and Conditions

REGISTRATION / CONFIRMATION / CANCELLATION

Confirmation of registration is subject to payment of the registration fee to be due at the moment of registration. Registration deadline is April 28, 2014. For payments/registrations coming in after this point in time, confirmation will be handed out on site in our conference office. To become valid, reservations have to be accompanied by the debit advice or credit card for the total amount due. In case of cancellation of participation until March 18, 2014, 50% of the registration will be reimbursed. No further reimbursement will be made after this point in time unless you name us a person to replace yourself, who will take over your complete reservation. In those cases documents will be charged with a handling fee of € 20,-.

Should you have special wishes regarding billing specifications, please let us know when you are making your registration. Any later rewriting of invoices will be charged with a handling fee of € 20,-.

Prices are based on current rates of the respective service providers as well as on present VAT rates. It is hereby expressly noted that prices may be subject to alterations which are beyond our sphere of influence.

LEGAL BASIS

The conference organizer is bsh medical communications GmbH. Third parties entering into the agreement will be liable together with the participant towards the organizer as joint debtors for the invoice amount and for rebooking charges.

The right to program changes is expressly reserved. These may be no reason for cancellation of registrations. Registration fees are being collected by bsh medical communications GmbH.

The General Terms given above form the basis for registration. Oral agreements remain non-committal unless being confirmed in written form.



ovastat[®]
Treoosulfan

**DIE WAHL ZU HABEN HEISST,
ADHÄRENZ ZU STEIGERN!**
Vergleichbare Wirksamkeit;
ovastat[®] als Kapsel oder Infusion

ovastat[®]
Treoosulfan

ovastat[®] 1000/5000 mg, Pulver zur Herstellung einer Infusionslösung; ovastat[®] 250 mg Hartkapseln
Wirkstoff: Treoosulfan. **Zusammensetzung:** 1 Durchstechflasche ovastat[®] 1000/5000mg enthält 1000/5000 mg Treoosulfan zur Rekonstitution in 20 (100)ml Lösungsmittel. Eine ovastat[®] 250 mg Hartkapsel enthält 250mg Treoosulfan; andere Bestandteile: Maisstärke, Hypromellose, Magnesiumstearat, Gelatine, Titandioxid. **Anwendungsgebiete:** ovastat[®] 1000/5000 mg ist allein oder in Kombination mit anderen antineoplastisch wirksamen Substanzen angezeigt in der palliativen Therapie epithelialer Ovarialkarzinome der FIGO Stadien II-IV. Eine Monotherapie mit Treoosulfan ist angezeigt, wenn eine Kontraindikation gegen Cisplatin besteht. In allen anderen Fällen sollte Treoosulfan mit Cisplatin kombiniert werden. **ovastat[®] 250 mg Hartkapseln:** Palliative Monotherapie des fortgeschrittenen Ovarialkarzinoms nach Versagen platinhaltiger Standardtherapien. **Gegenanzeigen:** Überempfindlichkeit gegen Treoosulfan oder einen der sonstigen Bestandteile. Schwangerschaft und Stillzeit. Bestehende schwere Knochenmarkdepression. **ovastat[®] 250 mg Hartkapseln** zusätzlich: Leukozytenzahl unter 2000/ μ l und/oder Thrombozytenzahl unter 100.000/ μ l; erst wenn das Blutbild auf normale Werte zurückgekehrt ist, sollte eine Therapie mit Treoosulfan begonnen werden. **Nebenwirkungen:** Die dosisbegrenzende Nebenwirkung ist die im Allgemeinen reversible Myelosuppression. **Häufigkeitsangaben:** Sehr häufig ($\geq 1/10$), häufig ($\geq 1/100$ bis $< 1/10$), gelegentlich ($\geq 1/1000$ bis $< 1/100$), selten ($\geq 1/10000$ bis $< 1/1000$), sehr selten ($< 1/10000$). **Gutartige, bösartige und unspezifische Neubildungen (einschl. Zysten und Polypen):** Gelegentlich: Unter Langzeittherapie einer oralen Treoosulfangabe akute nicht lymphatische Leukämie; akute myeloische Leukämie. **Blut, Lymphsystem:** Häufig: Myelosuppression (Neutropenie, Thrombopenie, Anämie). Im Allgemeinen haben Leuko- und Thrombozyten nach 28 Tagen ihren Ausgangswert wieder erreicht. Da die Störungen der Knochenmarkfunktion kumulativ sind, ist ab dem 3. Zyklus das Blutbild in kürzeren Abständen zu kontrollieren, besonders bei Kombination mit anderen Therapieformen, die das Knochenmark angreifen, wie Radiotherapie. **Endokrin:** Sehr selten: M. Addison. **Stoffwechsel, Ernährung:** Sehr selten: Hypoglykämie. **Nervensystem:** Sehr selten: Parästhesien. **Herz:** Sehr selten: Kardiomyopathie. **Atemwege, Brust, Mediastinum:** Sehr selten: allergische Alveolitis, Pneumonie, Lungenfibrose. **Gastrointestinal:** ovastat[®] 1000/5000 mg: Sehr häufig: Nausea, Erbrechen. ovastat[®] 250 mg Hartkapseln: Häufig: abdominelle Beschwerden; gelegentlich: Stomatitis (insbesondere nach Kauen der Kapsel). **Leber, Galle:** ovastat[®] 250 mg Hartkapseln: Sehr selten: Ikterus. **Haut, Unterhautzellgewebe:** Sehr häufig: Alopezie, bronzefarbene Pigmentierung der Haut. Sehr selten: Erythema, Urtikaria, Sklerodermie, Psoriasis. **Niere, Harnwege:** Sehr selten: hämorrhagische Zystitis. **Allgemein:** Sehr selten: pseudo-grippale Beschwerden. **Verabreichungsort:** ovastat[®] 1000/5000 mg: Sehr selten: im Falle eines Extravasates schmerzhafte entzündliche Reaktionen des Gewebes. **Verschreibungspflichtig.** medac GmbH, Fehlandtstr. 3, D-20354 Hamburg. Stand: Oktober 2012

¹Hilger RA et al. Cancer Chemother Pharmacol 2000; 45: 483-488.

medac
onkologie

Poster

PO No 1, ABSTRACT No 32

Evaluation of 25OHD3 in serum of patients with vulvar cancer and benign vulvar lesions

D. Salehin, B. Hemmerlein (Krefeld, D); M. Thill (Frankfurt, D);
C. H. Wirsing von König, M. Friedrich (Krefeld, D)

PO No 2, ABSTRACT No 33

Prospective investigation of 25(OH)D3 serum concentration following UVB narrow band phototherapy in patients with psoriasis and atopic dermatitis

A. Weinhold, R. Obeid, Th. Vogt, J. Reichrath (Homburg/Saar, D)

PO No 3, ABSTRACT No 34

Single nucleotide polymorphisms (SNPs) in genes involved in the vitamin D endocrine system are associated with risk for cutaneous basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs)

M. Koreng, S. Reichrath, A. Weinhold, S. Gräber, Th. Vogt,
J. Reichrath (Homburg/Saar, D)

PO No 4, ABSTRACT No 35

Imatinib exerts inhibitory effects on vitamin D3 metabolism

L. M. Mehlig, C. Garve, J. T. Tauer, M. Suttrop, A. Bauer (Dresden, D)

PO No 5, ABSTRACT No 36

Genetic variants (SNPs) of genes involved in skin pigmentation are associated with 25(OH)D serum concentration

R. Saternus, S. Gräber (Homburg/Saar, D); S. Pilz (Graz, A);
M. Kleber (Freiburg, D); W. März (Mannheim, D);
Th. Vogt, J. Reichrath (Homburg/Saar, D)

Poster

PO No 6, ABSTRACT No 37

Combination of Vitamin D and COX-2 Inhibitors in Breast Cancer Cell Lines

M. Thill (Frankfurt, D); K. Reichert, A. Woeste (Lübeck, D);
M. Friedrich (Krefeld, D); D. Fischer, F. Köster (Lübeck, D)

PO No 7, ABSTRACT No 38

Effect of Cotinine Blood Serum Level on Vitamin-D Blood Serum Level Among Women Smokers in the United States

R. Manavi Kiano, B. P. Alston-Mills (Raleigh, NC, USA)

PO No 8, ABSTRACT No 39

Expression of Vitamin D receptor in squamous epithelial vulvar cancer and vulvar intraepithelial neoplasia

M. Friedrich (Krefeld, D); M. Thill (Frankfurt, D);
B. Hemmerlein, D. Salehin (Krefeld, D)

PO No 9, ABSTRACT No 40

Evaluation of 25OHD3 in serum of patients with vulvar cancer and benign vulvar lesions

D. Salehin, B. Hemmerlein (Krefeld, D); M. Thill (Frankfurt, D),
C. H. Wirsing von König, M. Friedrich (Krefeld, D)

PO No 10, ABSTRACT No 41

Differential expression of nuclear vitamin D receptor (VDR) cofactors contributes to the resistance of melanoma cell lines against the antiproliferative effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)

V. Planz, Th. Vogt, J. Reichrath (Homburg/Saar, D)

Faculty

Benedikt **Albert**, Göttingen, Germany
 PD Dr. med. Chalid **Assaf**, Krefeld, Germany
 Dr. med. Jörg Thomas **Bittenbring**, Homburg/Saar, Germany
 Prof. Carsten **Carlberg**, PhD, Kuopio, Finland
 Prof. Tai C. **Chen**, PhD, Boston/MA, USA
 Prof. Frank R. **de Gruijl**, MSc, PhD, Leiden, The Netherlands
 Prof. Dr. med. Michael **Friedrich**, Krefeld, Germany
 Prof. Dr. rer. nat. Dr. med. habil. Christoph **Geilen**, Hamburg, Germany
 William B. **Grant**, PhD, San Francisco/CA, USA
 Uwe **Gröber**, Essen, Germany
 Prof. Michael F. **Holick**, PhD, MD, Boston/MA, USA
 Prof. Glenville **Jones**, BSc, PhD, Kingston/ON, Canada
 Prof. Asta **Juzeniene**, PhD, Oslo, Norway
 Dr. Lars **Kattner**, Saarbrücken, Germany
 Prof. Dr. med. Clayton **Kraft**, Krefeld, Germany
 Dr. med. Rolfdieter **Krause**, Berlin, Germany
 Prof. Dr. med. Winfried **März**, Mannheim, Germany
 Prof. Johan Emilian **Moan**, Oslo, Norway
 Prof. Julia A. **Newton-Bishop**, PhD, Leeds, United Kingdom
 José Manuel **Ordóñez-Mena**, MSc, Heidelberg, Germany
 Prof. J. Wesley **Pike**, BS, MS, PhD, Madison/WI, USA
 Prof. Dr. med. Jörg **Reichrath**, Homburg/Saar, Germany
 Dr. Natacha **Rochel**, Illkirch, France
 apl.-Prof. Dr. rer. nat. Klaus **Römer**, Homburg/Saar, Germany
 Dr. Katarzyna **Sokolowska**, Warsaw, Poland
 Prof. Dr. med. Jörg **Spitz**, Schlangenbad, Germany
 PD Dr. med. Marc **Thill**, Frankfurt, Germany
 Dr. Donald L. **Trump**, MD, FACP, Buffalo/NY, USA
 Dr. rer. nat. Anja **Uhmann**, Göttingen, Germany
 Prof. Reinhold **Vieth**, PhD, Toronto/ON, Canada
 Univ.-Prof. Dr. med. Thomas **Vogt**, Homburg/Saar, Germany
 Prof. JoEllen **Welsh**, PhD, Rensselaer/NY, USA
 Prof. Dr. med. Armin **Zittermann**, Bad Oeynhausen, Germany

Poster authors

Prof. Dr. med. Michael **Friedrich**, Krefeld, Germany
 M. **Koreng**, Homburg/Saar, Germany
 Kiano **Manavi**, Raleigh/NC, USA
 Dr. Lysann Michaela **Mehling**, Dresden, Germany
 Viktoria Luise **Planz**, Homburg/Saar, Germany
 PD Dr. med. Darius **Salehin**, Krefeld, Germany
 Roman **Saternus**, Homburg/Saar, Germany
 PD Dr. med. Marc **Thill**, Frankfurt, Germany
 Annett **Weinhold**, Homburg/Saar, Germany

General information

ORGANIZING COMMITTEE

M. Friedrich, J. Reichrath and Th. Vogt

SCIENTIFIC BOARD

C. Carlberg (Kuopio, FI)
M. Friedrich (Krefeld, D)
M. F. Holick (Boston, USA)
J. Reichrath (Homburg/Saar, D)
Th. Vogt (Homburg/Saar, D)

DATE AND PLACE

Mercure Hotel Krefelder Hof
Uerdinger Straße 245 | 47800 Krefeld | Germany
Friday, May 02, 2014 and Saturday, May 03, 2014
Registration at 7.15 am

HOTEL

Rooms are available at special rates at Mercure Hotel Krefelder Hof. Please make your reservation indicating the code "Vitamin D 2014". Please note that we cannot guarantee the availability of rooms.

Further information:
www.mercure.com
Phone: +49 (0) 2151-584-0
E-Mail: h5404@accor.com

CONFERENCE LANGUAGE

English

SATELLITENSYMPOSIUM LANGUAGE

German

CONFERENCE OFFICE AND OPENING HOURS

Daily opening times: 1 hour before the conference begins until 30 minutes after end of the meeting.

CONFERENCE PHONE

+49 (0) 172-2128605

General information

ORGANIZER / INFORMATION

bsh medical communications GmbH
Liebfrauenstraße 7 | D-40591 Düsseldorf, Germany
Phone: +49 (0) 211 - 770 589 - 0 | Fax: - 29
info@medical-communications.de
www.medical-communications.de

CERTIFICATION

The conference will be certified by the Ärztekammer Nordrhein and by the AIO in the DKG e.V.

For German participants please bring your barcode to record the CME points.

EVENING RECEPTION MAY 02, 2014

Ticket, per person € 30,-

The Get-together takes place
Friday, May 02, 2014 at 7.30 pm

"Krefelder Rennbahn" – Derby restaurant
An der Rennbahn 4 | 47800 Krefeld, Germany

The ticket includes food and beverage.

Dresscode: business casual

REGISTRATION FEES

Conference ticket (2 days) incl. Satellite symposium,
per person € 300,-*

Reduced price for students (2 days), per person € 100,-*

Conference ticket – Saturday afternoon
(Satellite symposium only) € 50,-*

All tickets include lunch, coffee breaks and softdrinks during the conference.

*19% VAT inclusively

GRAPHIC DESIGN

ProScript Michael Hellmessen | www.proscript-mh.de

COVER PICTURE

© everythingpossible - Fotolia.com

Under the Auspices of



Deutsche Krebsgesellschaft e.V. (DKG)



Deutsche Krebshilfe e.V. (DKH)



Förderverein der Frauenklinik e.V.

Supported by



Deutsche Forschungsgemeinschaft (DFG)

Special thanks to

EXHIBITORS



AbbVie Deutschland | € 1.000,-* Deltastar Nutrients | € 1.800,-*



Vitalstoffe für optimale Gesundheit



Biosimilars

Hexal AG
€ 1.400,-*



Manfred Holtkamp Elektronik GmbH
€ 1.000,-*



Immunodiagnostic Systems GmbH
€ 1.400,-*



Immundiagnostik AG
€ 1.400,-*



Roche Pharma AG
€ 1.000,-*

SPONSORS



Diasorin Deutschland GmbH | € 350,-*



Kardialgut GmbH | € 1.000,-*



Procter & Gamble Germany GmbH & Co. Operations OHG
€ 1.000,-*



ADVERTISEMENT



medac Gesellschaft für klinische Spezialpräparate mbH
€ 1.000,-*

* Sponsoring amount – Disclosure of sponsoring support according to §20 section 5 of the transparency allegation FSA-Codex / circles of experts.

